

# DCAT TOP Industry NEWS

*BUSY WEEK? Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*



DCAT  
**AFTER** THE SHOW *A Member Company Networking Event*

BARCELONA 2016

WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

## **1. Biogen Seeks Successor to CEO**

Biogen's Chief Executive Officer George Scangos will be leaving the company in the coming months after a successor has been identified. Biogen said it will begin a search for his successor immediately and will consider both internal and external candidates. Dr. Scangos has been at Biogen for six years. Biogen expects the transition to occur over a period of a few months, and in the interim, Dr. Scangos will continue to serve as CEO. [Read More](#)

## **2. Celgene, Jounce Therapeutics In Collaboration Worth Up To \$2.6 Billion**

Jounce Therapeutics, a Cambridge, Massachusetts-based immuno-oncology company, has formed a global strategic collaboration with Celgene worth up to \$2.6 billion for developing and commercializing immuno-oncology treatments. Under the collaboration, Jounce will receive an upfront payment of \$225 million, a \$36-million equity investment by Celgene, and up to an additional \$2.3 billion in future milestone payments. [Read More](#)

## **3. Novartis Reports \$500 Million in 2Q Procurement Savings**

As part of its second-quarter earnings release, Novartis provided an update of its productivity initiatives. In total, the company's productivity initiatives generated gross savings of approximately \$700 million in the second quarter. This total included \$500 million in savings from Procurement. [Read More](#)

## **4. EMA Accepts MAA for Samsung Bioepis Biosimilar of Humira**

The European Medicines Agency has accepted for review the marketing authorization application from Samsung Bioepis for its biosimilar referencing Humira (adalimumab), an anti-arthritis biologic drug. Humor, marketed by Abbie, is the company's leading product with global 2015 sales of \$14 billion. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. [Read More](#)

## **5. EMA Accepts MAA For Mylan's Biosimilar of Amgen's Neulasta**

The European Medicines Agency has accepted for review Mylan's marketing authorization application for its proposed biosimilar of pegfilgrastim, the active ingredient in Amgen's Neulasta. Neulasta is one of Amgen's top-selling drugs with 2015 revenues of \$4.7 billion. [Read More](#)

## **6. FDA Cites GSK UK Manufacturing Facility for GMP Deviations**

The US Food and Drug Administration has posted a Warning Letter to GlaxoSmithKline for deviations from current good manufacturing practice for active pharmaceutical ingredients at the company's manufacturing facility in Worthing, UK. Among the deviations noted by the agency were issues related to cross-contamination from a dedicated penicillin manufacturing area to non-dedicated areas. [Read More](#)

## 7. [Patheon Prices IPO](#)

Patheon, a CDMO for active pharmaceutical ingredients and drug products, has announced the pricing of its initial public offering of 29,761,905 of its ordinary shares at a public offering price of \$21.00 per share. Patheon is selling 25 million ordinary shares, and the selling stockholder named in the prospectus is selling 4,761,905 ordinary shares. The company began trading on the New York Stock Exchange on July 21, 2016. [Read More](#)

## 8. [MilliporeSigma Plans \\$115 Million Expansion in US](#)

MilliporeSigma plans to build a new campus in Burlington, Massachusetts that will serve as a major hub for the North American life science business of its parent company, Merck KGaA. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space. [Read More](#)

## 9. [Galenica To Acquire Relypsa for \\$1.53 Billion](#)

Galenica Group, a Bern, Switzerland-based specialty pharmaceutical company, has agreed to acquire Relypsa, a Redwood City, California-based biopharmaceutical company for approximately \$1.53 billion. The deal gives Galenica full global rights to Relypsa's Veltassa (patiromer), a potassium binder in oral suspension for treating hyperkalemia and also strengthens Galenica's position in the US. [Read More](#)

## 10. [World Bank Provides B. Braun \\$33 Million For Indonesia Manufacturing Plant](#)

The International Finance Corporation, a member of the World Bank Group, will provide a loan equal to IDR 450 billion (\$33 million) to B. Braun Melsungen's operations in Indonesia to finance construction of a local manufacturing facility for large-volume parenterals (LVPs). LVPs are now largely imported into Indonesia. B. Braun is a German manufacturer of medical devices and pharmaceutical products and services. [Read More](#)

### **\*\*Upcoming DCAT Event\*\***

#### **[DCAT Announces Its Newest Member Networking Event](#)**

Enjoy all that Barcelona has to offer while making valuable industry connections at **DCAT After the Show**, DCAT's newest member networking event held immediately following CPhI Worldwide in Barcelona on Wednesday, October 5, from 6:00 PM to 8:30 PM. Located at the beautiful Casa Llotja de Mar, this venue is just steps away from the Gothic Quarter and Port of Barcelona, offering member company representatives the perfect opportunity to engage with colleagues they may have missed at the show before attending their customer events.

Registration for this event will open July 20, 2016. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!*

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)